Alpelisib

Name: Alpelisib
Availability: alpelisib-357347.html

Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients
Product Name:Alpelisib
CAS No.:1217486-61-7
Standard:In-house Standards
Price(USD):Negotiable
Company:Shenzhen Haorui Pharmatech Co., Ltd.

Send Inquiry

Favorites

Similar Products

Nosiheptide Premix 56377-79-8

Celecoxib

99% up GMP DMF Phentolamine 50-60-2

Cabazitaxe

Levofloxacin

99% up GMP DMF L-Carnitine 10017-44-4

Pemetrexed disodium

3-Fluoro-4-methylphenylisothiocyanate

Pyridine, 2-(phenylsulfonyl)-

Agomelatine

Basic Info

Grade: Pharmaceutical Grade

Factory Location: Hubei

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no

Payment Terms: L/C

Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients.

Send your message to this supplier

From:
To:
Shenzhen Haorui Pharmatech Co., Ltd.
Send a Copy to this Email
Message:
Upload Images / Files
- Supports jpg, jpeg, png,
gif, pdf, doc, docx,
xls, xlsx, txt, rar and zip
- Max upload 3 files;
Max total size: 3MB
(0/3)

Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now
Verification: